Novavax To Initiate COVID-19 Phase 2 Influenza Combination, Stand Along Vaccine Trials
WASHINGTON (dpa-AFX) - Novavax, Inc. (NVAX) Friday announced the start of the phase 2 trial for COVID-19 influenza combination and stand-alone influenza vaccine candidates. The dose-confirming
Source: finanznachrichten.de